Lex Machina, a leader in legal analytics and a LexisNexis company, unveiled an API Developer Portal.
Bayer will present a range of new clinical data at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22), being held April 2-4, 2022, in Washington, D.C. Data from KERENDIA® (finerenone), a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA)1 and asundexian, an investigational oral Factor XIa inhibitor2 will be presented at the meeting. These data highlight Bayer’s ongoing commitment to patients with cardiovascular (CV) and kidney diseases.
Pfizer announced positive top-line results from the company’s year-long Phase III trial of etrasimod for the treatment of ulcerative colitis (UC). Pfizer plans to pursue regulatory filings for the drug during 2022.
AstraZeneca will showcase the company’s early oncology portfolio that it believes has the potential to transform the oncology treatment landscape at the upcoming American Association for Cancer Research (AACR) conference.
Kythera Labs, a leading data science platform provider for healthcare, announced financing led by Espresso Capital and advised by Brentwood Capital Advisors to support unprecedented growth and enhance its current offerings.
Seattle-based Icosavax’s stock plunged more than 60 percent on March 25 after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial.
A new study from France counters conventional understandings regarding artificial sweeteners and their relationship with cancer.
Verantos – a market leader in high-validity real-world evidence generation – announced that along with its research partners, the company accomplished a significant step forward in applying advanced real-world evidence approaches to non-alcoholic steatohepatitis (NASH).
Pfizer announced March 24 that the company received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the vaccine candidate PF-06928316 (RSVpreF), intended to prevent infections caused by a respiratory syncytial virus (RSV).
Moderna reported positive interim results from the Phase II/III KidCOVE trial of the company’s mRNA COVID-19 vaccine for children six months to under two years and also two to six years of age.
